2-(4-氨基苯)-1,1,1,3,3,3-六氟-2-丙醇 | 722-92-9

• 物质功能分类: 有机原料 - 氨基化合物 - 含氧基氨基化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(4-氨基苯)-1,1,1,3,3,3-六氟-2-丙醇
• 中文别名: 4-(六氟-2-羟基异丙基)苯胺；2-(4-氨基苯基)-1,1,1,3,3,3-六氟-2-丙醇
• 英文名称: 2-(4-aminophenyl)-1,1,1,3,3,3-hexafluoro-2-propanol
• 英文别名: 2-(4-aminophenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol；4-(1-hydroxy-1-trifluoromethyl-2,2,2-trifluoroethyl)aniline；4--anilin；p-Amino-α,α-bis-(trifluormethyl)-benzylalkohol；4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenylamine
• CAS: 722-92-9
• 化学式: C₉H₇F₆NO
• mdl: MFCD00039258
• 分子量: 259.151
• InChiKey: TZEJXCIGVMTMDY-UHFFFAOYSA-N

物化性质

• 熔点：
  147-152 °C
• 沸点：
  292.9±40.0 °C(Predicted)
• 密度：
  1.505±0.06 g/cm3(Predicted)
• 稳定性/保质期：
  常温常压下稳定，避免与氧化物接触。

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  46.2
• 氢给体数：
  2
• 氢受体数：
  8

安全信息

• 危险等级：
  IRRITANT
• 危险等级：
  6.1
• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R20/22,R36/37/38
• 海关编码：
  2922199090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  请将容器密封后，放入一个紧密封装的储存器中，并存放在阴凉、干燥的地方。

SDS

Name:	2-(4-Aminophenyl)-1 1 1 3 3 3-hexafluoro-2 -propanol Material Safety Data Sheet
Synonym:	4-(Hexafluoro-2-hydroxyisopropyl)anilin
CAS:	722-92-9

Section 1 - Chemical Product MSDS Name:2-(4-Aminophenyl)-1 1 1 3 3 3-hexafluoro-2 -propanol Material Safety Data Sheet
Synonym:4-(Hexafluoro-2-hydroxyisopropyl)anilin

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
722-92-9	2-(4-Aminophenyl)-1,1,1,3,3,3-hexafluo		unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 722-92-9: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 155 - 156 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H7F6NO
Molecular Weight: 259.15

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide, hydrogen fluoride gas.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 722-92-9 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-(4-Aminophenyl)-1,1,1,3,3,3-hexafluoro-2 -propanol - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 722-92-9: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 722-92-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 722-92-9 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

2-(4-氨基苯基)-1,1,1,3,3,3-六氟-2-丙醇可用来制备双酚AF。双酚AF（即六氟双酚A：2,2-双(4-羟基苯基)六氟丙烷），主要用于作为氟橡胶硫化促进剂。

制备

在四颈瓶中，将0.02摩尔对甲苯磺酸加入到0.1摩尔苯胺中，并用氮气置换。加热至一定温度后，在搅拌下缓慢滴加0.3摩尔HFA·3H₂O（约需30分钟滴加完毕）。滴加完成后，继续在110℃回流8小时后停止反应，冷却至室温凝结成白色固体。加入乙醚溶解，过滤并洗涤滤液。将滤液通过旋转蒸发去除乙醚及其他低沸点物质，并进行干燥处理，最终得到2-(4-氨基苯基)-1,1,1,3,3,3-六氟-2-丙醇粗品。该方法的收率为90.2％（通过GC-MS测定），纯度达到97.9％。

反应信息

• 作为反应物：
  描述：

  2-(4-氨基苯)-1,1,1,3,3,3-六氟-2-丙醇 在 盐酸 、 sodium nitrite 、 potassium iodide 作用下， 以 水 为溶剂， 反应 1.0h， 以74%的产率得到1,1,1,3,3,3-hexafluoro-2-(4-iodophenyl)propan-2-ol
  参考文献：
  名称：

  4-(1,1,1,3,3,3-六氟-2-羟基异丙-2-基)苯基硅烷衍生物作为肝X受体激动剂的设计、合成及构效关系

  摘要：

  肝 X 受体 (LXR) α 和 LXRβ 是在脂质代谢中起关键作用的核受体，LXR 配体是代谢紊乱的有吸引力的候选药物。在这里，我们报告了 4-（1,1,1,3,3,3-hexafluoro-2-hydroxyprop-2-yl）苯基硅烷衍生物的结构发展，作为 LXR 激动剂，具有甲硅烷基官能团作为疏水药效团，基于结构已知的磺胺类 LXR 激动剂 T0901317。大多数合成的化合物对 LXR 表现出激动活性，但 LXR 亚型选择性取决于硅原子上的取代基。其中，三（正丙基）衍生物12显示出有效的 LXR 激动活性，具有中等的 α 亚型选择性，而二甲基苯基甲硅烷基衍生物19显示适度的β-选择性。这些结果表明，硅烷可以作为 LXR 激动剂的磺胺部分的替代品，并且是开发新型亚型选择性 LXR 激动剂的有希望的结构选择。

  DOI：

  10.1016/j.bmc.2022.116792
• 作为产物：
  描述：

  N-(1-Hydroxy-1-trifluoromethyl-2,2,2-trifluoroethyl)aniline 以4%的产率得到
  参考文献：
  名称：

  CHKANIKOV, N. D.;SVIRIDOV, V. D.;ZELENIN, A. E.;GALAXOV, M. V.;KOLOMIETS,+, IZV. AN CCCP. CEP. XIM.,(1990) N, S. 383-389

  摘要：

  DOI：

文献信息

• Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150231142A1

  公开（公告）日：2015-08-20

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• [EN] FUSED-RING PYRIMIDIN-4(3H)-ONE DERIVATIVES, PROCESSES FOR THE PREPARATION AND USES THEREOF<br/>[FR] DERIVES DE LA PYRIMIDIN-4(3H)-ONE A CYCLES FUSIONNES, SPN PROCEDE DE PREPARATION ET SES UTILISATIONS
  申请人：SANKYO CO

  公开号：WO2003106435A1

  公开（公告）日：2003-12-24

  AbstractNovel compounds of the following formula (I) and pharmacologically acceptable salt and esters thereof can modulate LXR function and as a result show excellent anti-arteriosclerotic and anti-inflammatory activity:wherein:A represents aryl or heteroaryl;R1, R2 and R3 are the same or different and each represents hydrogen, hydroxyl, nitro, cyano, amino, halogen, carboxy, carbamoyl, mercapto, alkyl, haloalkyl, alkylcarbonyloxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, dialkylamino, alkylcarbonylamino, N-(alkylcarbonyl)-N-(alkyl)amino, alkoxycarbonylamino, N-(alkoxycarbonyl)-N-(alkyl)amino, alkylsulfonylamino, N-(alkylsulfonyl)-N-(alkyl)amino, haloalkylsulfonylamino, N-(haloalkylsulfonyl)-N-(alkyl)amino, alkylcarbonyl, alkoxycarbonyl, alkylaminocarbonyl or dialkylaminocarbonyl group, or R1 and R2 together are alkylenedioxy;R4 and R5 are the same or different and each represents hydrogen, hydroxyl, amino, halogen, mercapto, alkyl, haloalkyl, alkoxy, alkoxycarbonyl or alkylthio;X represents hydrogen, hydroxyl, halogen, alkoxy or haloalkoxy; andY represents an optionally substituted alkyl, cycloalkyl, heterocyclyl, aryl, cycloalkylalkyl, heterocyclylalkyl or aralkyl group.

  新化合物具有以下式（I）的结构，其药学上可接受的盐和酯可以调节LXR功能，从而表现出优秀的抗动脉粥样硬化和抗炎活性：其中：A代表芳基或杂环芳基；R1、R2和R3相同或不同，每个代表氢、羟基、硝基、氰基、氨基、卤素、羧基、氨基甲酰基、巯基、烷基、卤代烷基、烷基羰氧基、烷氧基、烷硫基、烷磺基、烷基氨基、二烷基氨基、烷基羰基氨基、N-（烷基羰基）-N-（烷基）氨基、烷氧羰基氨基、N-（烷氧羰基）-N-（烷基）氨基、烷磺酰氨基、N-（烷磺酰基）-N-（烷基）氨基、卤代烷基磺酰氨基、N-（卤代烷基磺酰基）-N-（烷基）氨基、烷基羰基、烷氧羰基、烷基氨基羰基或二烷基氨基羰基，或R1和R2一起是亚烷二氧基；R4和R5相同或不同，每个代表氢、羟基、氨基、卤素、巯基、烷基、卤代烷基、烷氧基、烷氧羰基或烷硫基；X代表氢、羟基、卤素、烷氧基或卤代烷氧基；Y代表可选择取代的烷基、环烷基、杂环烷基、芳基、环烷基烷基、杂环烷基烷基或芳基烷基。
• Anti-Viral Compounds
  申请人：DeGoey David A.

  公开号：US20100317568A1

  公开（公告）日：2010-12-16

  Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

  描述了一种有效抑制丙型肝炎病毒（“HCV”）复制的化合物。本发明还涉及制备这种化合物的方法、包含这种化合物的组合物，以及使用这种化合物治疗HCV感染的方法。
• Discovery of Potent and Orally Bioavailable Inverse Agonists of the Retinoic Acid Receptor-Related Orphan Receptor C2
  作者：Stefan von Berg、Yafeng Xue、Mia Collins、Antonio Llinas、Roine I. Olsson、Torbjörn Halvarsson、Maria Lindskog、Jesper Malmberg、Johan Jirholt、Nina Krutrök、Marie Ramnegård、Marie Brännström、Anders Lundqvist、Matti Lepistö、Anna Aagaard、Jane McPheat、Eva L. Hansson、Rongfeng Chen、Yao Xiong、Thomas G. Hansson、Frank Narjes

  DOI：10.1021/acsmedchemlett.9b00158

  日期：2019.6.13

  The further optimization of a recently disclosed series of inverse agonists of the nuclear receptor RORC2 is described. Investigations into the left-hand side of compound 1, guided by X-ray crystal structures, led to the substitution of the 4-aryl-thiophenyl residue with the hexafluoro-2-phenyl-propan-2-ol moiety. This change resulted in to compound 28, which combined improved drug-like properties

  描述了最近公开的核受体RORC2的反向激动剂系列的进一步优化。在X射线晶体结构的引导下，对化合物1左侧的研究导致将4-芳基-硫代苯基残基替换为六氟-2-苯基-丙-2-醇部分。这种变化产生了化合物28，该化合物将改善的类药物特性与良好的细胞效力和明显更低的剂量相结合，使用了早期剂量即可进行预测。口服给药后，小鼠胸腺中双阳性T细胞数量的减少证明了体内靶标的参与。
• TYK2 INHIBITORS AND USES THEREOF
  申请人：Nimbus Lakshmi, Inc.

  公开号：US20160251376A1

  公开（公告）日：2016-09-01

  The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.

  本发明提供了化合物、其组合物以及使用这些化合物来抑制TYK2并治疗TYK2介导的疾病的方法。